Aldeyra Therapeutics, Inc. - Special Call Transcript
Good morning, and welcome to the Aldeyra Therapeutics conference call. (Operator Instructions)
I would now like to hand the conference over to Joshua Reed, Chief Financial Officer. Thank you, sir. Please go ahead.
Thank you, and good morning, everyone. On the call with me are Dr. Todd Brady, Aldeyra's President and Chief Executive Officer; and David McMullin, our Chief Business Officer.
Please turn to Slide 2. This presentation and various remarks which may be made during this presentation, contain forward-looking statements regarding Aldeyra and investigational drug candidate, reproxalap. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Aldeyra's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.
These statements reflect Aldeyra's current views with respect to future events and are based on assumptions
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
